Concepedia

Stephanie Hund

SH

Statistics

Publications

2

Citations

40

H-Index

2

Active since

2021

Affiliations

Agilent Technologies (United States)(Current)

Stephanie Hund is an author at Agilent Technologies (United States) specializing in pd-l1 blockade, programmed death-ligand 1 biomarker, and cancer biomarkers.

Publications per year

2021–2024

2

Publications

2

Intrapatient Tumor Heterogeneity in IHC Interpretation Using PD-L1 IHC 22C3 pharmDx

Megan Kalpakoff, Stephanie Hund, Jeanette Musser et al. · Applied immunohistochemistry & molecular morphology · 2021 · 28 citations · Full text

, , +14

Contribution of tumour and immune cells to <scp>PD‐L1</scp> expression as a predictive biomarker in metastatic triple‐negative breast cancer: exploratory analysis from <scp>KEYNOTE</scp>‐119

Javier Cortés, Eric P. Winer, Oleg Lipatov et al. · The Journal of Pathology Clinical Research · 2024 · 12 citations · Full text

, , +17

1–2 of 2